CN111343979A - 用于海洛因依赖和物质使用障碍的马吲哚治疗 - Google Patents

用于海洛因依赖和物质使用障碍的马吲哚治疗 Download PDF

Info

Publication number
CN111343979A
CN111343979A CN201880070488.1A CN201880070488A CN111343979A CN 111343979 A CN111343979 A CN 111343979A CN 201880070488 A CN201880070488 A CN 201880070488A CN 111343979 A CN111343979 A CN 111343979A
Authority
CN
China
Prior art keywords
mazindol
heroin
substance
group
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880070488.1A
Other languages
English (en)
Chinese (zh)
Inventor
亚历山大·C·佐伊尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NLS Pharmaceutics AG
Original Assignee
NLS 1 Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NLS 1 Pharma AG filed Critical NLS 1 Pharma AG
Publication of CN111343979A publication Critical patent/CN111343979A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201880070488.1A 2017-09-07 2018-09-06 用于海洛因依赖和物质使用障碍的马吲哚治疗 Pending CN111343979A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555469P 2017-09-07 2017-09-07
US62/555469 2017-09-07
PCT/IB2018/001138 WO2019058172A1 (en) 2017-09-07 2018-09-06 MAZINDOLE TREATMENT FOR HEROID DEPENDENCE AND DISORDER RELATED TO THE USE OF PSYCHOACTIVE SUBSTANCES

Publications (1)

Publication Number Publication Date
CN111343979A true CN111343979A (zh) 2020-06-26

Family

ID=64316589

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880070488.1A Pending CN111343979A (zh) 2017-09-07 2018-09-06 用于海洛因依赖和物质使用障碍的马吲哚治疗

Country Status (9)

Country Link
US (1) US11596622B2 (https=)
EP (1) EP3678661A1 (https=)
JP (1) JP7593619B2 (https=)
KR (1) KR20200085730A (https=)
CN (1) CN111343979A (https=)
BR (1) BR112020004506A2 (https=)
CA (1) CA3074054A1 (https=)
MX (1) MX2020002560A (https=)
WO (1) WO2019058172A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217987A (en) * 1989-10-30 1993-06-08 Berger Stephen P Dopamine uptake inhibitors in reducing substance abuse and/or craving
US20130011483A1 (en) * 2010-03-31 2013-01-10 Supernus Pharmaceuticals, Inc. Formulations of mazindol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
FR2899476B1 (fr) 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
WO2009029308A1 (en) 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
US9687445B2 (en) * 2012-04-12 2017-06-27 Lts Lohmann Therapie-Systeme Ag Oral film containing opiate enteric-release beads
JP6584745B2 (ja) 2014-04-09 2019-10-02 和久 前田 抗肥満薬の効果を向上させる組成物の製造方法。
ES2884973T3 (es) 2016-03-09 2021-12-13 Nls Pharmaceutics Ag Comprimido multicapa de mazindol de IR/SR y su utilización para el tratamiento del trastorno por déficit de atención/hiperactividad (ADHD)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217987A (en) * 1989-10-30 1993-06-08 Berger Stephen P Dopamine uptake inhibitors in reducing substance abuse and/or craving
US20130011483A1 (en) * 2010-03-31 2013-01-10 Supernus Pharmaceuticals, Inc. Formulations of mazindol

Also Published As

Publication number Publication date
CA3074054A1 (en) 2019-03-28
US11596622B2 (en) 2023-03-07
EP3678661A1 (en) 2020-07-15
US20210161865A1 (en) 2021-06-03
JP2020533295A (ja) 2020-11-19
MX2020002560A (es) 2020-07-13
WO2019058172A1 (en) 2019-03-28
BR112020004506A2 (pt) 2020-09-15
JP7593619B2 (ja) 2024-12-03
KR20200085730A (ko) 2020-07-15

Similar Documents

Publication Publication Date Title
US20230233584A1 (en) Extended release 5-ht receptor agonists for neurological conditions
KR101688996B1 (ko) 통증 치료에 있어서 트라마돌 및 셀레콕시브를 포함하는 조성물
US20080021074A1 (en) Pharmaceutical Compositions and Related Methods of Treatment
KR20070107805A (ko) 옥시코돈 및 날록손 함유 제형
JP2022160647A (ja) マジンドールのｉｒ／ｓｒ多層錠剤及び該錠剤の注意欠陥／多動性障害（ａｄｈｄ）の治療のための使用
JP6228212B2 (ja) 記憶能力を改善するための向知性組成物
JP7593619B2 (ja) ヘロイン依存症及び物質使用障害のためのマジンドール治療
US20250288540A1 (en) Methods and compositions for pain management
CN111050800A (zh) 血清素3受体激动剂对疼痛的治疗
JP2007532559A (ja) 神経因性疼痛、線維筋痛および慢性疲労症候群の治療のための組成物および方法
HK40002539A (en) A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
JP2013049643A (ja) 選択的セロトニン再取り込み阻害薬の誘発嘔吐に対する制吐剤
HK1173379B (en) Compositions comprising tramadol and celecoxib in the treatment of pain

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination